Multiple Sclerosis: Making a Timely Diagnosis and Selecting Optimal Treatment Choices

This activity contains:

  • A CME/CE-certified Text Module, a web-based program

This activity was released on January 8, 2016 and is valid for one year.
Requests for credit must be made no later than January 7, 2017.

Purpose
The overall goal of this activity is to educate neurologists, primary care physicians, multiple sclerosis (MS) specialists, nurses, and other healthcare professionals involved in the treatment and management of multiple sclerosis about important issues related to the timely and accurate diagnosis of MS and how to construct optimal treatment strategies for their patients with MS.

Activity Overview
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS that affects approximately 400,000 people in the United States. Although the exact etiology of MS is unknown, it is likely the result of a complex interaction among genetic and environmental factors and the immune system.

MS is diagnosed based on clinical findings and ancillary tests such as magnetic resonance imaging (MRI) of the brain and spinal cord and examination of cerebrospinal fluid. Diagnosis traditionally could be made only after repeat attacks; however, the 2010 McDonald criteria allow diagnosis of MS with a first clinical episode. Because axonal loss can be present in asymptomatic, early disease, early diagnosis and intervention are critical. A 2014 revision of the MS clinical subtype definitions originally developed in 1996 aimed to better characterize clinical descriptive terminology as well as MRI and other imaging techniques used to diagnose and manage MS.

Relapsing-remitting MS (RRMS), characterized by a clinical pattern with periodic relapses followed by remissions, initially develops in 80% of patients. Other, less common types of MS include secondary progressive (SPMS), primary progressive (PPMS), and progressive-relapsing (PRMS).

There are numerous treatment options for relapsing forms MS, including several, newer oral disease-modifying therapies (DMTs). In addition, a number of emerging treatment options look promising. These new and emerging DMTs may provide a more efficacious, individualized therapeutic approach; more favorable methods of administration; and/or a lower frequency of infusions that may improve patient adherence to therapy and overall clinical outcomes. The increasing number of first- and second-line treatment options for RRMS, the variable course of the disease, and patient lifestyles and expectations make therapeutic decisions quite challenging.

Finding effective treatment options for the progressive forms of MS has been a much more daunting process. In fact, there are currently no US Food and Drug Administration–approved therapies for the treatment of PPMS, although a number of studies are evaluating several of the approved agents for RRMS for their effect in PPMS.

Clinicians who work with patients with MS must be up to date on the important issues related the diagnosis and management of this disease.

Target Audience

This activity is intended for neurologists, primary care physicians, multiple sclerosis specialists, nurses, and other healthcare professionals involved in the treatment and management of multiple sclerosis. 

Learning Objectives

  • Describe best practices to make an accurate and timely diagnosis of multiple sclerosis (MS)
  • Construct optimum treatment regimens for patients with MS
  • Discuss the importance of evaluating disease activity and communicating with patients regarding mechanisms of disease progression and treatment complications
  • Evaluate emerging data on investigational agents being studied for the treatment of MS
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Attendance
Course opens: 
01/08/2016
Course expires: 
01/07/2017
Cost:
$0.00
Rating: 
0
Chairperson 

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Co-Chief Editor, Multiple Sclerosis and Related Disorders
The Icahn School of Medicine at Mount Sinai
New York, New York

PHYSICIAN ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

NURSING CONTINUING EDUCATION
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com 

INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, during the period, 1/8/2016, through, 1/7/2017, participants must read the learning objectives and faculty disclosures and study the educational activity.  

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. 

SYSTEM REQUIREMENTS
PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader* 
MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh. 


Disclosures of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterReported Financial Relationship
Fred D. Lublin, MD   

Co-Chief editorMultiple Sclerosis and Related Disorders
Consulting agreements/advisory boards/DSMB: AbbVie; Acorda Therapeutics; Actelion Pharmaceuticals, Inc.; Akros Pharma Inc; Amgen, Inc; Bayer HealthCare Pharmaceuticals; BBB Technologies; Biogen IDEC Inc; Celgene Corporation; EMD Serono, Inc; Forward Pharma; MedImmune; Novartis Pharmaceuticals Corp; Osmotica Pharmaceutical Corp; Questcor/Malinckrodt; Receptos, Inc; Roche/Genentech; Sanofi/Genzyme; Taisho Toyama Pharmaceutical Co Ltd; Teva Neuroscience, Inc; TG Therapeutics Inc; XenoPort, Inc;
Research funding:  Biogen IDEC Inc; Celgene Corp; Genzyme, Inc; National Institutes of Health; National Multiple Sclerosis Society; Novartis Pharmaceuticals Corp; Sanofi; Teva Neuroscience, Inc; Transparency Life Sciences;
Financial interested/stock ownership:  Cognition Pharmaceuticals, Inc


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or ManagerReported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Amanda Glazar, PhDNothing to disclose
Andrea FunkNothing to disclose
Laura GilsdorfNothing to disclose
Linda Gracie-King, MS    Nothing to disclose
Ronald Viggiani, MDNothing to disclose
Deborah Middleton, MSNothing to disclose
Jocelyn Timko, BSNothing to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and AXIS Medical Education do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There is no fee for this educational activity.

This activity is provided by

This activity is supported by an educational grant from Genentech.

AXIS 1276-TXT

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Attendance

Accreditation Period

Course opens: 
01/08/2016
Course expires: 
01/07/2017

Price

Cost:
$0.00
Please login or register to take this course.